Samal B, Jones S, Brownlee R W, Morrison F, Hoogstraten B, Caoili E, Baker L
Cancer Treat Rep. 1978 Jan;62(1):19-22.
Chromomycin A3 was administered iv to 26 patients in a phase I trial. The maximum tolerated dose established in this study was 0.75 mg/m2/day iv X 5 days. The drug was then given to 48 evaluable patients with far-advanced disseminated breast cancer. Two short partial remissions and one clinical improvement were seen. Toxic manifestations consisted of frequent and usually reversible renal toxicity, nausea and vomiting, occasional thrombocytopenia, hypocalcemia, and two instances of semicoma. Drug toxicity may have contributed to the death of two patients.
在一项I期试验中，对26名患者静脉注射了放线菌素A3。该研究确定的最大耐受剂量为0.75毫克/平方米/天，静脉注射，共5天。然后，该药物被给予48名可评估的晚期播散性乳腺癌患者。观察到两例短期部分缓解和一例临床改善。毒性表现包括频繁且通常可逆的肾毒性、恶心和呕吐、偶尔的血小板减少症、低钙血症以及两例半昏迷。药物毒性可能导致了两名患者死亡。
